↓ Skip to main content

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

Overview of attention for article published in Cancer Chemotherapy & Pharmacology, November 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
12 Mendeley
Title
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors
Published in
Cancer Chemotherapy & Pharmacology, November 2016
DOI 10.1007/s00280-016-3189-1
Pubmed ID
Authors

James Spicer, Sheeba Irshad, Joo Ern Ang, Deborah Enting, Rebecca Kristeleit, Martina Uttenreuther-Fischer, Karine Pemberton, Katy Pelling, David Schnell, Johann de Bono

Abstract

The combination of afatinib, an irreversible ErbB family blocker, with paclitaxel and bevacizumab was assessed in patients with advanced solid tumors. This phase I study used a 3 + 3 design to determine the maximum tolerated dose (MTD) of afatinib combined with paclitaxel and bevacizumab. Safety, pharmacokinetics, and anti-tumor activity were also assessed. The starting dose was oral afatinib 40 mg once daily plus intravenous paclitaxel (fixed dose 80 mg/m(2), Days 1, 8, and 15 of a 4-week cycle) and intravenous bevacizumab 5 mg/kg every 2 weeks. Twenty-nine patients were enroled. The afatinib dose was de-escalated to 30 mg and then 20 mg after 2/6 and 2/5 evaluable patients developed dose-limiting toxicities at 40 and 30 mg, respectively, when combined with paclitaxel and bevacizumab 5 mg/kg. The bevacizumab dose was subsequently escalated to 10 mg/kg, and MTD was defined as afatinib 20 mg plus paclitaxel 80 mg/m(2) and bevacizumab 10 mg/kg. Frequent (any grade) treatment-related adverse events (AEs) included diarrhea (83%), rash/acne (83%), fatigue (79%), mucosal inflammation (59%), and nausea (59%). Based on overall safety, bevacizumab was amended to 7.5 mg/kg for the recommended phase II dose. Pharmacokinetic analyses suggested no relevant drug-drug interactions. Three (10%) confirmed partial responses were observed; 15 (52%) patients had stable disease. The recommended phase II dose schedule was afatinib 20 mg/day with paclitaxel 80 mg/m(2) (Days 1, 8, and 15 every 4 weeks) and bevacizumab 7.5 mg/kg every 2 weeks. At this dose schedule, AEs were manageable, and anti-tumor activity was observed.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 25%
Student > Master 3 25%
Student > Bachelor 2 17%
Other 1 8%
Professor 1 8%
Other 2 17%
Readers by discipline Count As %
Medicine and Dentistry 3 25%
Unspecified 2 17%
Biochemistry, Genetics and Molecular Biology 2 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 17%
Nursing and Health Professions 1 8%
Other 2 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2017.
All research outputs
#4,660,015
of 9,076,202 outputs
Outputs from Cancer Chemotherapy & Pharmacology
#270
of 708 outputs
Outputs of similar age
#161,223
of 310,980 outputs
Outputs of similar age from Cancer Chemotherapy & Pharmacology
#8
of 19 outputs
Altmetric has tracked 9,076,202 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 708 research outputs from this source. They receive a mean Attention Score of 2.6. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,980 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.